ArticleCNS neuroscience & therapeutics2021
A novel DNA repair-related nomogram predicts survival in low-grade gliomas.
Article in CNS neuroscience & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- ARGLU1 in Glioma: A Novel Potential Regulator of Splicing, DNA Repair, and Therapeutic Resistance.Cells · 2026Review
- Integrating machine learning and retrospective cohort to explore the effects of AEDs on the prognosis of LGG and identify related molecular targets.BMC pharmacology & toxicology · 2026Article
- Predicting Recurrence Risk of Glioblastoma Based on Preoperative-Postoperative Longitudinal MRI: A Multicenter Study.Bioengineering (Basel, Switzerland) · 2026Article
- Identification of Crucial Genes Associated With MYCN-Driven Neuroblastoma Based on Single-Cell Analysis and Machine Learning.Cancer medicine · 2025Article
- A novel predictive model utilizing retinal microstructural features for estimating survival outcome in patients with glioblastoma.Clinical neurology and neurosurgery · 2025Article
- Diabetes-associated differentially expressed genes as prognostic biomarkers and therapeutic targets in endometrial cancer: a comprehensive molecular analysis.Frontiers in oncology · 2025Article
- A Nomogram for Predicting Survival in Patients with SARS-CoV-2 Omicron Variant Pneumonia Based on Admission Data.Infection and drug resistance · 2025Article
- A Glycolysis and gluconeogenesis-related model for breast cancer prognosis.Cancer biomarkers : section A of Disease markers · 2024Article
- Machine learning predicts cuproptosis-related lncRNAs and survival in glioma patients.Scientific reports · 2024Article
- Prediction model for poor short-term prognosis in patients with chronic subdural hematoma after burr hole drainage: a retrospective cohort study.Neurosurgical review · 2024Article
- Value analysis ofTranslational cancer research · 2024Article
- Article
- A Novel Predictive Model Utilizing Retinal Microstructural Features for Estimating Survival Outcome in Patients with Glioblastoma.Research square · 2024Article
- Article
- Integration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma.Frontiers in pharmacology · 2024Article
- The mitotic cell cycle-associated nomogram predicts overall survival in lung adenocarcinoma.Cancer medicine · 2023Article
- A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy.Discover oncology · 2023Article
- Prediction of long-term mortality in patients with ischemic stroke based on clinical characteristics on the first day of ICU admission: An easy-to-use nomogram.Frontiers in neurology · 2023Article
- A novel DNA repair-related nomogram predicts survival in low-grade gliomas.CNS neuroscience & therapeutics · 2021Article
- Multi-center real-world data-driven web calculator for predicting outcomes in IDH-mutant gliomas: Integrating molecular subtypes and treatment modalities.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe aimed to create a tumor recurrent-based prediction model to predict recurrence and survival in patients with low-grade glioma.
methodsThis study enrolled 291 patients (188 in the training group and 103 in the validation group) with clinicopathological information and transcriptome sequencing data. LASSO-COX algorithm was applied to shrink predictive factor size and build a predictive recurrent signature. GO, KEGG, and GSVA analyses were performed for function annotations of the recurrent signature. The calibration curves and C-Index were assessed to evaluate the nomogram's performance.
resultsThis study found that DNA repair functions of tumor cells were significantly enriched in recurrent low-grade gliomas. A predictive recurrent signature, built by the LASSO-COX algorithm, was significantly associated with overall survival and progression-free survival in low-grade gliomas. Moreover, function annotations analysis of the predictive recurrent signature exhibited that the signature was associated with DNA repair functions. The nomogram, combining the predictive recurrent signature and clinical prognostic predictors, showed powerful prognostic ability in the training and validation groups.
conclusionAn individualized prediction model was created to predict 1-, 2-, 3-, 5-, and 10-year survival and recurrent rate of patients with low-grade glioma, which may serve as a potential tool to guide postoperative individualized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.